Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?

A number of new approaches to diabetes therapy are currently undergoing clinical trials, including those involving stimulation of the pancreatic β-cell with the gut-derived insulinotropic hormones (incretins), GIP and GLP-1. The current review focuses on an approach based on the inhibition of dipeptidyl peptidase IV (DP IV), the major enzyme responsible for degrading the incretins in vivo. The rationale for this approach was that blockade of incretin degradation would increase their physiological actions, including the stimulation of insulin secretion and inhibition of gastric emptying. It is now clear that both GIP and GLP-1 also have powerful effects on β-cell differentation, mitogenesis and survival. By potentiating these pleiotropic actions of the incretins, DP IV inhibition can therefore preserve β-cell mass and improve secretory function in diabetics,